Intuitive Surgical Reports Strong Second Quarter Results
Intuitive Surgical (NASDAQ: ISRG), a recognized leader in minimally invasive healthcare technologies, reported remarkable financial outcomes for its second quarter.
Noteworthy Highlights from Q2
During this quarter, Intuitive experienced notable growth in various operational metrics:
- da Vinci surgical procedures increased significantly by approximately 17% compared to the same quarter last year.
- A total of 395 da Vinci surgical systems were placed, surpassing previous year's placements by a considerable margin.
- This quarter's placements included the advanced da Vinci 5 systems, with 180 units deployed, a substantial increase from the prior year's 70.
- The installed base of da Vinci systems reached 10,488, representing a robust 14% increase from last year.
- Intuitive's second-quarter revenue reached $2.44 billion, reflecting a 21% increase over the previous year’s $2.01 billion.
- The company's GAAP net income attributable to Intuitive was $658 million, or $1.81 per diluted share, marking an improvement from $527 million, or $1.46 per diluted share from the previous year.
- Additionally, non-GAAP net income attributable to Intuitive was $798 million, translating to $2.19 per diluted share.
Regulatory Milestones
In recent developments, Intuitive obtained European certification for its da Vinci 5 system catering to adult and pediatric usage in minimally invasive procedures. The company also received clearance in Japan for this system across various surgical specialties, excluding cardiac procedures.
Financial Overview
The operational success of the quarter has significantly contributed to the company's positive financial outlook. Gross profits, income from operations, and net income—all measured both on GAAP and non-GAAP basis—paint a promising picture of the company's financial health:
- Second-quarter instruments and accessories revenue climbed to $1.47 billion, up 18% compared to $1.24 billion last year.
- Systems revenue for Q2 was reported at $575 million, a noticeable increase from $448 million previously.
- Total gross profit reported was an impressive $1.62 billion.
Strategic Initiatives Moving Forward
Intuitive's commitment to broadening the scope of its innovative technologies continues as CEO Dave Rosa articulated the company's focus on enhancing care delivery and providing better outcomes for patients and healthcare teams alike.
Looking Ahead to 2025
For the full year 2025, Intuitive anticipates continued growth:
- The company expects worldwide da Vinci procedure growth between 15.5% to 17%.
- Projected non-GAAP gross profit margins are estimated to remain between 66% and 67% of revenue.
- Operating expenses are expected to grow by 10% to 14% in 2025.
Additional Information
Intuitive's ongoing commitment to innovation emphasizes their vision of transforming healthcare for the benefit of patients worldwide. More extensive financial details and supplementary information are available in the Investor Relations section of their website.
Contact Information
For inquiries, contact the Investor Relations team at Intuitive Surgical: (408) 523-2161.
Frequently Asked Questions
What were the key financial highlights for Intuitive Surgical in Q2?
Intuitive Surgical reported a revenue increase to $2.44 billion, a 21% rise from last year, with a net income of $658 million.
How many da Vinci systems were placed this quarter?
The company placed 395 da Vinci surgical systems in the second quarter.
What growth in surgical procedures did Intuitive experience?
da Vinci surgical procedures grew by approximately 17% compared to the same period last year.
What regulatory successes did Intuitive achieve recently?
Intuitive received European certification for the da Vinci 5 system and regulatory clearance in Japan.
What is Intuitive's outlook for 2025?
The company anticipates worldwide da Vinci procedure growth of 15.5% to 17% with a non-GAAP gross profit margin between 66% and 67% of revenue.
